Sigma Healthcare (ASX:SIG) said the pharmaceutical wholesaler agreement recently finalized by the Australian Government is expected to have minimal impact on the company's guidance for fiscal 2025 earnings before interest and taxes, according to a Thursday filing with the Australian bourse.
The conditions of the five-year agreement will start from January 2025, with full run-rate benefits expected to be achieved from July 2026 due to its staggered implementation over the next 18 months, the filing said.
The agreement, reached between the government, the Department of Health and Aged Care, and the National Pharmaceutical Services Association, will govern commercial terms of pharmaceutical wholesale in Australia, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。